Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Dec 01, 2022 11:23pm
187 Views
Post# 35145279

RE:RE:Silver lining

RE:RE:Silver liningHow will they attract somebody for the oncology manager they reupped the job offer a week ago? This is freakin misleading, maybe not intentionally, but it just makes no sense to search somebody to fill this job with the situation they are in now.


SPCEO1 wrote: Tomorrow will be rough but there really never has been any value given to cancer, so with lower costs during the pause, earnings should be better. And only one analyst, the most recent one from Jones, had ascribed any value for cancer. So, technically, he should be the only one lowering his price target. Somehow, the others will likely do so also anyway. 

It was suspicious that they had a non-cancer focused Q3 call and now I suppose we know why. 

SABBOBCAT wrote: The stock price doesn't reflect any value for oncology so we have nothing to lose... Right???? Tomorrow is going to be rough 




<< Previous
Bullboard Posts
Next >>